therapy for dry age-related macular degeneration (AMD), today announced clinical data from its Phase 1/2a clinical trial evaluating RPESC-RPE-4W, a proprietary retinal pigment epithelium (RPE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback